Smith & Nephew plc: Q2 and H1 2025 Results Summary
Business Context and Reporting Period
Smith & Nephew plc, a global medical technology company, reported its second quarter and first half results for the period ended June 28, 2025. The company operates across three primary business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The reporting period included 125 trading days, two fewer than the prior year.
Key Financial Metrics
| Metric | H1 2025 ($m) | H1 2024 ($m) | Change |
|---|---|---|---|
| Revenue | 2,961 | 2,827 | +4.7% (Reported) / +5.0% (Underlying) |
| Operating Profit | 429 | 328 | +30.6% |
| Trading Profit | 523 | 471 | +11.2% |
| Trading Profit Margin | 17.7% | 16.7% | +100 bps |
| EPS (Basic) | 33.5 cents | 24.5 cents | +36.6% |
| EPSA (Adjusted) | 42.9 cents | 37.6 cents | +14.1% |
| Cash from Operations | 568 | 368 | +54.3% |
| Free Cash Flow | 244 | 39 | +528.3% |
| Net Debt | 2,747 | 2,709 | Stable |
Material Changes vs. Prior Period
- Revenue Growth Acceleration: Q2 underlying revenue growth accelerated to 6.7% (reported 7.8%), driven by a 110bps FX tailwind. All regions and business units grew ahead of Q1.
- Margin Expansion: Trading profit margin expanded by 100 basis points to 17.7%, driven by revenue leverage and operational savings from the "12-Point Plan."
- Cash Flow Improvement: Trading cash conversion improved significantly by 33 percentage points to 93%, primarily due to favorable working capital movements and a reduction in Day Sales of Inventory (DSI) by 46 days.
- Restructuring Costs: Restructuring charges decreased substantially to $8 million in H1 2025, down from $62 million in H1 2024, as the company nears completion of its transformation plan.
- Segment Performance:
- Orthopaedics: Underlying growth of 5.0%; US Reconstruction showed sequential improvement for the fourth consecutive quarter.
- Sports Medicine & ENT: Underlying growth of 5.7% (10.2% excluding China headwinds from Volume Based Procurement).
- Advanced Wound Management: Underlying growth of 10.2%, led by a rebound in Bioactives and double-digit growth in Devices.
Guidance, Outlook, and Management Commentary
- Full Year Guidance Unchanged: The company expects underlying revenue growth of around 5.0% (reported ~5.5%) and a trading profit margin expansion to between 19.0% and 20.0% for the full year 2025.
- Shareholder Returns: Announced an additional $500 million share buyback to be executed in the second half of 2025. The interim dividend was increased by 4.2% to 15.0 cents per share.
- Tariff Impact: The outlook includes an expected net impact of $15 to $20 million from tariffs in 2025, based on announced measures and mitigations.
- Innovation: CEO Deepak Nath highlighted that three-quarters of H1 growth came from products launched in the last five years, including new hip implants, robotics, and wound care technologies.
- Risks: Key risks include China's Volume Based Procurement (VBP) impacting Sports Medicine, potential headwinds from proposed Medicare reimbursement changes for skin substitutes in 2026, and global economic conditions affecting elective procedures.
Investor Verification Checklist
- China VBP Impact: Verify the timeline for the annualization of China VBP headwinds in Sports Medicine and the expected recovery in Q3/Q4.
- Medicare Reimbursement: Monitor the finalization of proposed Medicare changes for skin substitutes and their potential impact on 2026 profitability.
- Buyback Execution: Confirm the timing and volume of the announced $500 million share buyback in H2 2025.
- Inventory Levels: Track the sustainability of the 46-day reduction in Day Sales of Inventory (DSI) and its effect on future working capital.
- Tariff Mitigation: Assess the effectiveness of the company's strategies to mitigate the projected $15-$20 million tariff impact.